UPDATED: As PDUFA looms Sanofi punts a $35M partnership

A little more than a year after Sanofi ($SNY) stepped in to sign a development deal with Pozen, the pharma giant has stepped back out just weeks ahead of a scheduled PDUFA date. Chapel Hill, NC-based Pozen ($POZN) says the pharma giant and the biotech "mutually agreed" to end the partnership to develop a pair of new-and-improved aspirins dubbed PA8140 and PA32540. Sanofi paid $15 million in cash and promised up to $20 million more in precommercialization milestones to get the deal. Pozen CEO John Plachetka said the company would consider its strategic options, noting the drug is tackling a target market with more than 20 million consumers. Investors, though, weren't too happy with today's turn of events. Pozen's shares plunged 19% in morning trading. Pozen also has commercial names in place. PA8140 will be referred to as YOSPRALA 81/40 (enteric-coated aspirin 81 mg/immediate release omeprazole 40 mg) and PA32540 (enteric-coated aspirin 325 mg/immediate release omeprazole 40 mg) will be referred to as YOSPRALA 325/40. Release

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.